Madrigal pharmaceuticals highlights presentations at the liver meeting digital experience™, the american association for the study of liver diseases meeting november 13, 2020, including nash expert insights on the ongoing open label arm of resmetirom 52-week phase 3 maestro-nafld-1 trial

Conshohocken, pa., nov. 13, 2020 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), announced that dr. stephen harrison, m.d., medical director for pinnacle clinical research, san antonio, texas, and visiting professor of hepatology, oxford university, and principal investigator of the maestro studies, will make an oral presentation today at 4:30 pm et at the liver meeting digital experience™, the american association for the study of liver diseases meeting, november 2020 accessible via the product theaters and satellite symposium page. dr. harrison's presentation, based on data from studies with mgl-3196 (resmetirom), will also highlight key insights from three posters, which are available to registered attendees on the liver meeting digital experience™ website throughout the four-day meeting. resmetirom is the first orally administered, small-molecule, liver-directed, truly Β-selective thyroid hormone receptor (thr) agonist and is currently in phase 3 development for the treatment of nash patients both with biopsy-confirmed fibrosis stage 2-3 (clinicaltrials.gov nct03900429) and in presumed nash subjects diagnosed non-invasively (clinicaltrials.gov/nct04197479).
MDGL Ratings Summary
MDGL Quant Ranking